GSK touts 3-year data on RSV shot Arexvy after CDC's narrower …
WEB1 hour ago · In the trial, which looked at Arexvy’s ability to stop RSV-associated lower respiratory tract disease (LRTD) in people 60 and older, a single dose of GSK’s shot yielded a cumulative efficacy ...
GSK says RSV vaccine protects against disease over three seasons
WEB29 minutes ago · The results come from a large Phase 3 trial that supported Arexvy’s approval. Approximately 25,000 people in 17 countries were enrolled in the study, which compared Arexvy to placebo at several time points. Researchers calculated Arexvy’s efficacy against RSV-caused lower respiratory tract disease as 83% during the first season.
GSK RSV shot 43% effective against severe disease in third year
WEB5 hours ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK Presents Positive Data for AREXVY, Its Respiratory ... - BioSpace
WEB4 hours ago · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying medical conditions. Today’s results indicate that after a single dose of GSK’s RSV vaccine, cumulative efficacy …
GSK presents positive data for AREXVY, its respiratory syncytial …
WEBIndication for AREXVY. AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age and older; Individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. Important Safety Information for ...
GSK presents positive data for Arexvy, its respiratory syncytial …
WEBArexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older, including those who are at increased risk due to certain underlying medical conditions. Today's results indicate that after a single dose of GSK’s RSV vaccine, cumulative efficacy over three full RSV seasons was clinically ...
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease. Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older.